论文部分内容阅读
自1979年首次报道同胞异基因骨髓移植治疗慢性粒细胞白血病(CML)成功以来,有合适配型的异基因骨髓移植成为CML,特别是慢性期治疗的方法之一。本文报道了欧洲慢性粒细胞白血病骨髓移植协作组的病例资料,在移植前通过计分方式确定干细胞移植的危险因素,结果如下。 病人与方法 病人系1989年～1996年期间所进行的干细胞移植的病例,共3142例,年龄<20岁的355例,20～40岁1831例,>40岁的1056例;男1873例,女1269例;诊断到移植的时间≤12个月1547例,>12个月1595例;慢性期2301例,加速期417例,原始细胞危象等424例;匹配的同胞干细胞移植2411例,无关供者731例。危险因素计分:匹配同胞移植0分,无关供者1分;慢性期0分,加速期1分,原始细胞危象等2分;
Since the first reported in 1979 that sibling allogeneic bone marrow transplantation was successful in the treatment of chronic myelogenous leukemia (CML), allogenetic bone marrow transplantation with appropriate matching has become one of the methods for the treatment of CML, especially in the chronic phase. This article reports the case data of the European Union of CML Bone Marrow Transplantation Cooperative Group. The risk factors of stem cell transplantation are determined by scoring before transplantation. The results are as follows. Patients and Methods Patients were stem cell transplantation cases from 1989 to 1996, a total of 3142 cases, 355 cases were <20 years old, 1831 cases were 20 to 40 years old, 1056 cases were >40 years old; 1873 cases were men, women 1269 cases; 1547 cases diagnosed as having transplant time ≤12 months; 1595 cases>12 months; 2301 cases in chronic phase, 417 cases in accelerated phase, 424 cases of primary cell crisis, etc.; 2411 cases of matched sibling stem cells were transplanted. 731 cases. Risk factor scores: 0 for matched sibling transplantation, 1 for unrelated donor, 0 for chronic phase, 1 for accelerated phase, 2 points for primary cell crisis;